tbuckley/cabot-search huggingface dataset:
Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine
Authors: Kathryn Riley, Zachary Schwager, Marleigh Stern, Ruth Ann Vleugels, Alisa Femia
Journal: JAMA Dermatology (2019)

Discussion | Early exposure and mentorship opportunities are associated with higher rates of students pursuing careers in specific fields. 4 We examined associated dermatology residency programs, fellowships, and interest groups as proxies of opportunities for early dermatology exposure.Medical schools without early exposure opportunities correlated with higher proportions of SUIM.Sex diversity did not vary across groups.Our study is limited because defining dermatology exposure is difficult.The presence of dermatology fellowships may not guarantee significant exposure opportunities; however, we believe that fellowships require institutions to have educational infrastructures supportive of dermatology.Dermatology shadowing programs for students may be better exposure proxies, although more difficult to identify.Nonetheless, given the correlation between higher proportions of SUIM and institutions with limited dermatology exposure opportunities, such schools might benefit from targeted support.Opportunities for mentorship and funding for clinical rotations such as the American Academy of Dermatology diversity mentorship program 5 should be promoted.Dermatology faculty should be encouraged to engage in such mentorship.Partnerships between exposure-rich and exposure-poor schools could be facilitated.Dermatologists should be mindful of continuing mentorship and opportunities for SUIM choosing to pursue dermatology, including programmatic efforts. 6 To promote racial and ethnic diversity within dermatology and ensure the delivery of equitable and effective health care for an increasingly diverse population, further research into barriers limiting pursuit of dermatology careers by SUIM and the development of programs to address such barriers is needed.
Circulating tumor DNA may correlate with tumor size changes following therapy.
Authors: John Chang, Daniel Egert, Jessica Padniewski, Benjamin Johnson, Curt Bay, Tomislav Dragovich, Madappa N. Kundranda, Phillip Koo
Journal: Journal of Clinical Oncology (2019)

233 Background: Pancreatic cancer has significant mortality at five years, even in resectable disease. Recent effort has been dedicated to identify a more specific tumor marker for screening and assessing tumor response, in part because 10% of the population does not produce CA19-9. Detection and quantification of circulating tumor DNA (ctDNA) in the bloodstream is a novel concept for screening and treatment response assessment. This study examined possible correlations between ctDNA levels and various aspects of pancreatic cancer in a total of 17 patients receiving treatment at Banner MD Anderson Cancer Center. Methods: Present study is approved by our local IRB. Research was conducted according HIPPA regulation. Subjects on the present study were obtained from the list of patients participating in our ctDNA trial. A total of 17 subjects were identified from the list. Their ctDNA index levels were obtained from the sponsor (Chronyx) at baseline and following each cycle of the treatment. For each CT scan and each ctDNA study, they are considered the same time if they are obtained within 4 weeks of each other. The sizes of the primary tumor and the largest metastatic lesion were on a transverse image at the largest extent of the lesion. Data was analyzed with Spearman's correlation. Results: Baseline ctDNA levels did not correlate with patient demographic data (N = 17; gender, p = 0.63; age, p = 0.82), baseline size of primary mass on CT scan (N = 16; p = 0.85), baseline vessel involvement on CT Scan (N = 17; p = 0.58), presence of metastasis on CT scan (N = 17; p = 0.78), size of largest metastasis on CT scan (N = 17; p = 0.85), presence of peripancreatic lymph nodes on CT scan (N = 17; p = 0.45), or overall survival (N = 8; p = 0.6). However, there is a trend toward correlating the change in ctDNA and change in size on CT scan following treatment (N = 7; p = 0.12). Conclusions: ctDNA at baseline appears to be secreted independent of the primary tumor size, location, or presence of metastasis. However, changes in ctDNA does seem to correlate with changes in tumor size following treatment. Although our data was not statistically significant, this may be related to the low sample size. With larger sample size, it is expected that changes in ctDNA may prove to correlate with changes in tumor size.
Maintenance of Certification Status and Performance on a Set of Process Measures
Authors: Mark Jarrett
Journal: Annals of Internal Medicine (2019)

Letters19 February 2019Maintenance of Certification Status and Performance on a Set of Process MeasuresMark Jarrett, MD, MBA, MSMark Jarrett, MD, MBA, MSNorthwell Health, New Hyde Park, New York (M.J.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0635 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Gray and colleagues' article (1) showed the value of continuous professional learning on a validated set of quality measures. The results unfortunately reflect mediocre performance from physicians who both did and did not maintain certification 20 years after initial certification, which should be the article's key conclusion. How can we accept less than 60% adherence to hemoglobin A1c testing from either study group? Although I fully support the concept of MOC as a marker for physicians' educational engagement, we need to refocus our efforts less on supporting certificates and more on actual results. The knowledge gap may ...Reference1. Gray B, Vandergrift J, Landon B, Reschovsky J, Lipner R. Associations between American Board of Internal Medicine maintenance of certification status and performance on a set of Healthcare Effectiveness Data and Information Set (HEDIS) process measures. Ann Intern Med. 2018;169:97-105. [PMID: 29893788]. doi:10.7326/M16-2643 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Northwell Health, New Hyde Park, New York (M.J.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L18-0635. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAssociations Between American Board of Internal Medicine Maintenance of Certification Status and Performance on a Set of Healthcare Effectiveness Data and Information Set (HEDIS) Process Measures Bradley Gray , Jonathan Vandergrift , Bruce Landon , James Reschovsky , and Rebecca Lipner Maintenance of Certification Status and Performance on a Set of Process Measures Bradley Gray , Jonathan Vandergrift , Bruce Landon , James Reschovsky , and Rebecca Lipner Maintenance of Certification Status and Performance on a Set of Process Measures Alan R. Ertle Maintenance of Certification Status and Performance on a Set of Process Measures James J. Glazier and Amir Kaki Metrics 19 February 2019Volume 170, Issue 4Page: 283-284KeywordsConflicts of interestDisclosureHemoglobin ePublished: 19 February 2019 Issue Published: 19 February 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Deciphering the microbiome and virome composition of patients with Atopic Dermatitis and Eczema Herpeticum (ADEH+)
Authors: Livia S. Zaramela, Daiane R.B. Belgini, Marco A. Ramirez-Gama, Keli Johnson, Donald Y.M. Leung, Karsten Zengler
Journal: Journal of Allergy and Clinical Immunology (2019)
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
Authors: Hirva Mamdani, Bryan J. Schneider, Laith I. Abushahin, Thomas J Birdas, Kenneth Kesler, Ahran Lee, Heather Burney, Susan Perkins, Shadia Ibrahim Jalal
Journal: Journal of Clinical Oncology (2019)

5 Background: The standard of care for locally advanced esophageal adenocarcinoma(LA-EAC) is concurrent chemoradiation (CRT) followed by esophagectomy. Approximately 30% of patients (pts) achieve complete pathologic response (pCR) with this approach. The risk of relapse in the remaining 70% of pts is high, with 1-yr relapse free survival (RFS) of 50%. No adjuvant therapies have been shown to improve survival. Immune checkpoint inhibitors have activity in metastatic PD-L1 positive EAC. Preclinical studies have shown upregulation of PD-1 pathway with radiation +/- chemotherapy. Methods: We conducted a phase II study evaluating safety and efficacy of durvalumab (durva), a monoclonal antibody against PD-L1, in pts with LA-EAC and GE junction (GEJ) adenocarcinoma who do not achieve pCR after neoadjuvant CRT and R0 resection. Pts received durva 1500mg IV every 4 weeks for up to 1 yr after surgery. Primary objective was 1-yr RFS. Secondary objectives were incidence and severity of treatment related adverse events (AEs). Results: Twenty-four pts were enrolled from Apr 2016 to Jan 2018 (median age: 60yrs (range, 43-74)). Fourteen pts had GEJ adenocarcinoma and 10 had distal EAC. Eighteen received carboplatin/paclitaxel and six received cisplatin/5-FU concurrently with 50-50.4Gy radiation. Nineteen pts (79%) had positive lymph nodes at the time of surgery after neoadjuvant CRT, including three (12.5%) with N3, nine (37.5%) with N2, and seven (29%) with N1 disease. Among N0 pts, two had T3N0, one had T2N0, and two had T1N0 disease. At median follow-up of 11.7 mo (range 1.7-23.9 mo), seven pts (29%) have relapsed (five alive, two died); 17(67%) are disease free (six on treatment, seven completed treatment, three off-treatment); 1-yr and projected 26 mo RFS are 78.6% and 62.9%, respectively. Five pts (20.8%) developed grade 3 AEs: diarrhea (n = 1), hepatitis (n = 1), encephalopathy (n = 1), hyperglycemia (n = 1), hypoglycemia (n = 1). Most common grade 1 and 2 AEs were fatigue (33.3%), nausea (25.0%), and cough (20.8%). Conclusions: Adjuvant durva in pts with residual disease following trimodality therapy for EAC and GEJ adenocarcinoma is safe and feasible with 1-yr RFS of 78.6% compared to historical rate of 50%. Clinical trial information: NCT02639065.
Baseline Pancreatic Beta Cell Imaging After Pancreatic Transplantation Using Whole-Body 68Ga-DOTA-Exendin-4 PET/CT
Authors: Aashish Gambhir, Avani Jain, Indirani Elangovan, Shelley Simon
Journal: Clinical Nuclear Medicine (2019)

Whole pancreatic transplant and islet cells transplantation are currently available strategies aiming toward diabetes cure. Beta cell specific noninvasive functional imaging using novel PET radiotracers are now available and can be used for beta cell imaging and quantification. Herein we describe a spectrum of 2 cases demonstrating beta cell targeted imaging using Ga-DOTA-exendin-4 PET/CT in patients with diabetes after simultaneous pancreas-kidney transplantation.
The Natural History of Peanut and Egg Allergy and Predictors of Persistence: The Healthnuts Longitudinal Study, 6-Year-Old Follow-up.
Authors: Rachel Peters, Jennifer Koplin, Anne-Louse Ponsonby, Kirsten Perret, Shyamali C. Dharmage, Katrina Allen
Journal: Journal of Allergy and Clinical Immunology (2019)
HIV Partner Service Delivery Among Blacks or African Americans — United States, 2016
Authors: Shubha Rao, Wei Song, Mesfin S. Mulatu, Michele Rorie, Kevin O’Connor, Lamont Scales
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Identifying persons with human immunodeficiency virus (HIV) infection who are unaware of their infection status, linking them to HIV care, and reducing racial/ethnic disparities are important national HIV prevention goals (1). Blacks/African Americans (blacks)* are disproportionately affected by HIV infection in the United States. Although blacks represent 13% of the U.S. population (2), in 2017, 44% of diagnoses of HIV infection were in blacks, and the rate of new diagnoses in blacks (41.1 per 100,000 persons) was approximately eight times that of non-Hispanic whites (5.1) (3). HIV partner services are offered by health officials to persons with diagnosed HIV infection (index patients) and their sex- or needle-sharing partners, who are notified of their potential HIV exposure and offered HIV testing and related services (4). CDC analyzed 2016 data from the National HIV Prevention Program Monitoring and Evaluation system submitted by 59 health departments.
Abstract 18564: Redefining the Incidence and Impact of Acute Brain Injury After Neonatal Cardiac Surgery
Authors: Charlotte Verrall, Karen Walker, Alison Loughran-Fowlds, Chris Troedson, Julian Ayer, Jonathan Egan, Robert Halliday, Yishay Orr, Gary Sholler, Nadia Badawi, David S Winlaw
Journal: Circulation (2016)

Introduction: Whilst the reported incidence of acute brain injury (ABI) after paediatric cardiac surgery at all ages is around 2%, the true incidence and impact of ABI in neonatal cardiac surgery are not well defined and are the focus of this study. Methods: Neonates undergoing cardiac surgery with cardiopulmonary bypass (CPB) between July 2011 and December 2014 were identified. 134 patients were enrolled; 29 Norwood cases (22%) and 105 non-Norwood cases (78%). Clinical data were retrospectively collected including neurodevelopmental assessments (Bayley-III Scales) at one year. All imaging abnormalities as well as seizures and abnormal EEG results were recorded. Post-operative changes were considered ABI. Results: Preoperative neuroimaging or EEG abnormalities were evident in 6%, with an ABI rate of 17% post-operatively, totalling 23% with pre and/or post-operative neurologic abnormality. There were higher rates of abnormality in the Norwood group compared to the non-Norwood group (41% vs 18%, p=0.008). S...
Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden
Authors: Amy Shapiro, Ateefa Chaudhury, Nisha Jain, Elisa Tsao, Chris Barnowski, Jing Feng, Doris Quon
Journal: Blood (2018)
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis
Authors: Lasha Gogokhia, Kate Buhrke, Rickesha Bell, Brenden Hoffman, D. Garrett Brown, Christin Hanke-Gogokhia, Nadim J. Ajami, Matthew C. Wong, Arevik Ghazaryan, John F. Valentine, Nathan Porter, Eric Martens, Ryan O’Connell, Vinita Jacob, Ellen Scherl, Carl Crawford, W. Zac Stephens, Sherwood R. Casjens, Randy S. Longman, June L. Round
Journal: Cell Host & Microbe (2019)
Shorter Time Interval During Oral Food Challenge May Overlook The Real Threshold Dose
Authors: Tatsuki Fukuie, Yumiko Miyaji, Fumi Ishikawa, Makoto Irahara, Motoko Iwama, Miori Sato, Mayako Saito, Shinichiro Inagaki, Kiwako Yamamoto-Hanada, Masami Narita, Kenji Matsumoto, Yukihiro Ohya, Hirohisa Saito
Journal: Journal of Allergy and Clinical Immunology (2019)
Novel V1551L Mutation in SAMD9L Inhibits Cell Cycle Progression and Results in Pancytopenia That Progresses to MDS with Monosomy 7
Authors: Rebecca Ortolano, Dina S. Parekh, Benjamin J Rosen, Victoria Bryant, Dong-Hui Chen, Jeffery M. Klco, Wendy Herlihy Raskind, Kenneth Lieuw
Journal: Blood (2018)
Phase 1b study of andecaliximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma.
Authors: Kensei Yamaguchi, Taroh Satoh, Kei Muro, Atsuo Takashima, Takashi Ichimura, Daisuke Sakai, Shigenori Kadowaki, Keisho Chin, Toshihiro Kudo, Seiichiro Mitani, Shigehisa Kitano, Pankaj Bhargava, Marianna Zavodovskaya, JieJane Liu, Masato Fukui, Narikazu Boku
Journal: Journal of Clinical Oncology (2019)

137 Background: Matrix metalloproteinase 9 (MMP9) is a poor prognostic factor in gastric cancer. Preclinical studies suggest that MMP9 inhibition can relieve immune suppression, promote T cell infiltration, and potentiate benefits of checkpoint blockade. ADX is a monoclonal antibody that inhibits the enzymatic activity of MMP9. In this study, safety, PK, exploratory biomarkers, and preliminary efficacy of ADX alone and in combination with nivo were assessed. Methods: Up to 6 Japanese subjects were to be enrolled in Cohort 1 (monotherapy ADX 800 mg IV Q2W), followed by 10 subjects in Cohort 4 (nivo plus ADX). Treatment was continued until PD or unacceptable toxicity. Tumor biopsies were collected before treatment and at week 6. Results: As of August 2018, 8 and 10 subjects were dosed in Cohort 1 &amp; 4, respectively. All subjects received prior chemotherapy (median: 2, range: 1-4). In Cohort 1, Grade 3 AEs included anemia (25%), fatigue, general physical health deterioration, anorexia, and hydronephrosis (each 13%). All were not related to ADX. No DLTs nor responses were observed in Cohort 1. PK of ADX in Japanese subjects was similar to PK previously obtained in a non-Japanese population. The median t 1/2 was ~8.1 days after 800 mg dose. All circulating MMP9 was bound to ADX at 2 weeks after dosing in Cohort 1. In Cohort 4, ≥Grade 3 AEs were anemia (20%), DIC, fatigue, anorexia, hypoglycemia, cholangitis, AST increased, neutropenia, and cancer pain (each 10%). ORR was 40% (4/10) and median PFS &amp; OS have not been reached. Cohort 4 biomarker data will be presented. Conclusions: Preliminary safety data demonstrate a manageable safety profile for ADX alone and in combination with nivo. The combination appears to be promising. Clinical trial information: NCT02862535.
The early proximal αβ TCR signalosome specifies thymic selection outcome through a quantitative protein interaction network
Authors: Steven C. Neier, Alejandro Ferrer, Katelynn M. Wilton, Stephen E. P. Smith, April M. H. Kelcher, Kevin D. Pavelko, Jenna M. Canfield, Tessa R. Davis, Robert J. Stiles, Zhenjun Chen, James McCluskey, Scott R. Burrows, Jamie Rossjohn, Deanne M. Hebrink, Eva M. Carmona, Andrew H. Limper, Dietmar J. Kappes, Peter J. Wettstein, Aaron J. Johnson, Larry R. Pease, Mark A. Daniels, Claudia Neuhauser, Diana Gil, Adam G. Schrum
Journal: Science Immunology (2019)

Quantitative activity through the TCR-proximal protein network specifies thymic positive versus negative selection.
Abstract 19309: Use of Antithrombotic Therapy and 1-Year Outcome in Patients in Patients With Congestive Heart Failure and Impaired Ejection Fraction in Clinical Practice - Results of the Prospective EVITA-HF Registry
Authors: Uwe Zeymer, Wolfgang von Scheidt, Christian Zugck, Mathias Pauschinger, Mathias Hochadel, Jochen Senges
Journal: Circulation (2016)

Background: The optimal antithrombotic therapy in patients with congestive therapy still has to defined. Therefore we analysed the data of large registry to investgate the use of different antithrombotic therapies in clinical practice. Methods: The EVITA-HF registry prospectively enrolled 4260 patients with congestive heart failure and a left ventricular ejection fraction < 40 % in 25 centers. Patients were followed for at least 1 year. For this analysis we divided patients into 5 groups according to their antithrombotic therapy at discharge: no, single antiplatelet, dual antiplatelet, oral anticoagulation, oral anticoagilation + antiplatelet therapy. Results: The baseline characteristics and 1-year events are given in the table. Conclusion: There is an underuse of anticoagulation in patients with congestive heart failure and atrial fibrillation, while there was no clear indication for oral anticoagulation in about 1/3 of patients. Therefore guidelines are often no followed in clinical practice. Mortality...
The Euthymia Scale: A Clinimetric Analysis
Authors: Danilo Carrozzino, Andrea Svicher, Chiara Patierno, Carmen Berrocal, Fiammetta Cosci
Journal: Psychotherapy and Psychosomatics (2019)

Table S1.Exclusion criteria applied to diabetes type-2 outpatients and healthy subjects EXCLUSION CRITERIA Type 2 diabetes outpatients 1. a medical diagnosis of type-1 diabetes, current chronic illness other than type-2 diabetes 2. current psychiatric disorders as evaluated via the Mini International Neuropsychiatric Interview [S1] 3. cognitive deficits as assessed via the Mini Mental State Examination [S2] 4. mother tongue other than Italian Healthy subjects 1. diagnosis of type-2, type-1 diabetes, or current chronic medical illness 2. current psychiatric disorders as evaluated via the Mini International Neuropsychiatric Interview [S1] 3. self-reported cognitive deficits 4. mother tongue other than Italian
Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity
Authors: Peter Van Galen, Volker Hovestadt, Marc Wadsworth II, Travis Hughes, Gabriel Kenneth Griffin, Julia A. Verga, Jason Stephansky, Timothy J. Pastika, Jennifer Lombardi Story, Geraldine S. Pinkus, Olga Pozdnyakova, Ilene Galinsky, Richard M. Stone, Timothy A. Graubert, Alex K. Shalek, Jon C. Aster, Andrew A. Lane, Bradley E. Bernstein
Journal: Blood (2018)
Abstract 21310: ApoCIII RX19 Mutation Lowers the Production of ApoCIII and Increases the Clearance of VLDL-TG
Authors: Gissette Reyes-Soffer, Anstasiya Matveyenko, Maryam Khavandi, Wahida Karmally, Rajasekhar Ramakrishnan, Stephen Holleran, Henry Ginsberg, Toni Pollin
Journal: Circulation (2017)

The APOCIII R19X mutation (rs76353203), has been found in ~5% of the Lancaster Old Order Amish. It is a C -&gt;T substitution at the 55th nucleotide in human aolipoprotein C-III mRNA that prevents translation of mature apoC-III protein. The mutation decreases apoC-III levels by ~50% and confers favorable lipid profiles and less coronary artery calcification, providing evidence that ApoC-III deficiency is cardioprotective. This conclusion is supported by recent data in Danish and U.S. cohorts showing a 40% reduction in myocardial infarction rates in people with this mutation. The mechanisms whereby apoc-III deficiency exerts its effects are not fully understood. The aim of this study was to describe the fractional clearance rates (FCR) and production rates (PR) of apoB containing lipoproteins, apoCIII, and very low density lipoprotein (VLDL) tryglyceride (TG) in five Amish sibling pairs (CT vs. CC) discordant for the APOC3 R19X mutation and matched for age and sex. Methods: Sib pairs completed a 24-hr stable isotope kinetic study using leucine and glycerol. Blood samples were collected over 24-hr period. We measured plasma lipids and apoCIII by Elisa. We determined the FCR and PR of VLDL apoB, apoCIII, and VLDL-TG. Results: The CT subjects had a 38% decrease in baseline TG levels compared to CC. ApoCIII levels were reduced by 42% in the CT vs. CC. We observed reductions in VLDL-Chol (49%), IDL-Chol (52%), VLDL-TG(44%), and IDL-TG(39%) in the CT when compared to CC. The changes in plasma levels were due to an increase in the VLDL apoB FCR (p = 0.001) without significant changes in production. VLDL-TG FCR increased by 76% in the CT when compared to CC (p=0.03). We observed no differences in post-heparin plasma levels of hepatic and lipoprotein lipase activity in the CT vs. CC. The plasma changes in apoCIII were due to and increased FCR in the CT compared to CC. Conclusions: Reductions in plasma TG levels in heterozygous apoC-III deficient individuals is due to enhanced FCRs of VLDL-apoB and VLDL-TG.